Amgen Files Definitive Proxy Materials

TL;DR

Amgen filed its proxy statement, shareholders vote soon.

AI Summary

Amgen Inc. filed a Definitive Additional Materials proxy statement on April 17, 2025. This filing is related to the company's annual meeting and is not a preliminary proxy statement. No fee was required for this filing.

Why It Matters

This filing provides important information to shareholders regarding the company's annual meeting, including voting matters and executive compensation details.

Risk Assessment

Risk Level: low — This is a routine filing of proxy materials for an annual meeting, not indicating any unusual risks.

Key Players & Entities

• AMGEN INC. (company) — Registrant
• 0000950170-25-055585 (filing_id) — Accession Number
• 20250417 (date) — Filing Date

FAQ

From the Filing

0000950170-25-055585.txt : 20250417 0000950170-25-055585.hdr.sgml : 20250417 20250417172552 ACCESSION NUMBER: 0000950170-25-055585 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250417 DATE AS OF CHANGE: 20250417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 25848533 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 DEFA14A 1 amgn_issgl_defa_14a_2025.htm DEFA14A DEFA14A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑   Filed by the registrant       ☐  Filed by a party other than the registrant   Check the appropriate box:       ☐ Preliminary Proxy Statement       ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))       ☐ Definitive Proxy Statement       ☑ Definitive Additional Materials       ☐ Soliciting Material Pursuant to Section 240.14a-12     AMGEN INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant)   Payment of filing fee (check the appropriate box):       ☑ No fee required.       ☐ Fee paid previously with preliminary materials.       ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.   [Subsequent to this filing, Amgen Inc. sent the following summary communication to one or more investors and/or proxy advisory firms for their consideration in making their vote recommendations.]     Amgen 2025 Proxy Statement Key Highlights 2024 was another year of strong execution as we delivered record annual sales for twenty-one of our products and an ambitious research and development program agenda across our four therapeutic areas ( General Medicine , Rare Disease , Oncology , and Inflammation ). Highlights for the year include: • In General Medicine , based on positive MariTide™ ( maridebart cafraglutide ) Phase 2 data in chronic weight management, we initiated two Phase 3 MariTide clinical trials in adults living with obesity or overweight, with or without Type 2 diabetes in March 2025. A Phase 3 study of olpasiran in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein(a) (Lp(a)) continued to progress, moving us closer to what we hope will be a precision medicine to reduce cardiovascular risk for patients with Lp(a) elevation. • In Rare Disease , TEPEZZA® 1 was launched in Japan for the treatment of thyroid eye disease (TED), the first and only medicine approved in Japan for this indication. Based on positive Phase 3 data, UPLIZNA® 1 received FDA Breakthrough Therapy Designation 2 for the treatment of Immunoglobulin G4-related disease (IgG4-RD) and FDA orphan drug designation for the treatment of generalized myasthenia gravis (gMG). UPLIZNA was subsequently approved as the first and only treatment for IgG4-RD in April 2025. • In Oncology , we launched IMDELLTRA® in the U.S. for the treatment of extensive-stage small cell lung cancer, a complex and devastating disease that is hard to treat. BLINCYTO® received FDA approv